250 related articles for article (PubMed ID: 24028867)
21. Biochemical isolation of insoluble tau in transgenic mouse models of tauopathies.
Julien C; Bretteville A; Planel E
Methods Mol Biol; 2012; 849():473-91. PubMed ID: 22528110
[TBL] [Abstract][Full Text] [Related]
22. Apoptosis in oligodendrocytes is associated with axonal degeneration in P301L tau mice.
Zehr C; Lewis J; McGowan E; Crook J; Lin WL; Godwin K; Knight J; Dickson DW; Hutton M
Neurobiol Dis; 2004 Apr; 15(3):553-62. PubMed ID: 15056463
[TBL] [Abstract][Full Text] [Related]
23. Progranulin reduction is associated with increased tau phosphorylation in P301L tau transgenic mice.
Hosokawa M; Arai T; Masuda-Suzukake M; Kondo H; Matsuwaki T; Nishihara M; Hasegawa M; Akiyama H
J Neuropathol Exp Neurol; 2015 Feb; 74(2):158-65. PubMed ID: 25575133
[TBL] [Abstract][Full Text] [Related]
24. TOC1: a valuable tool in assessing disease progression in the rTg4510 mouse model of tauopathy.
Ward SM; Himmelstein DS; Ren Y; Fu Y; Yu XW; Roberts K; Binder LI; Sahara N
Neurobiol Dis; 2014 Jul; 67():37-48. PubMed ID: 24631720
[TBL] [Abstract][Full Text] [Related]
25. GFP-Mutant Human Tau Transgenic Mice Develop Tauopathy Following CNS Injections of Alzheimer's Brain-Derived Pathological Tau or Synthetic Mutant Human Tau Fibrils.
Gibbons GS; Banks RA; Kim B; Xu H; Changolkar L; Leight SN; Riddle DM; Li C; Gathagan RJ; Brown HJ; Zhang B; Trojanowski JQ; Lee VM
J Neurosci; 2017 Nov; 37(47):11485-11494. PubMed ID: 28986461
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements.
Asuni AA; Boutajangout A; Quartermain D; Sigurdsson EM
J Neurosci; 2007 Aug; 27(34):9115-29. PubMed ID: 17715348
[TBL] [Abstract][Full Text] [Related]
27. Axonal degeneration induced by targeted expression of mutant human tau in oligodendrocytes of transgenic mice that model glial tauopathies.
Higuchi M; Zhang B; Forman MS; Yoshiyama Y; Trojanowski JQ; Lee VM
J Neurosci; 2005 Oct; 25(41):9434-43. PubMed ID: 16221853
[TBL] [Abstract][Full Text] [Related]
28. Early-onset cognitive deficits and axonal transport dysfunction in P301S mutant tau transgenic mice.
Onishi T; Matsumoto Y; Hattori M; Obayashi Y; Nakamura K; Yano T; Horiguchi T; Iwashita H
Neurosci Res; 2014 Mar; 80():76-85. PubMed ID: 24406748
[TBL] [Abstract][Full Text] [Related]
29. Deletion of murine tau gene increases tau aggregation in a human mutant tau transgenic mouse model.
Ando K; Leroy K; Heraud C; Kabova A; Yilmaz Z; Authelet M; Suain V; De Decker R; Brion JP
Biochem Soc Trans; 2010 Aug; 38(4):1001-5. PubMed ID: 20658993
[TBL] [Abstract][Full Text] [Related]
30. Deficiency of terminal complement pathway inhibitor promotes neuronal tau pathology and degeneration in mice.
Britschgi M; Takeda-Uchimura Y; Rockenstein E; Johns H; Masliah E; Wyss-Coray T
J Neuroinflammation; 2012 Sep; 9():220. PubMed ID: 22989354
[TBL] [Abstract][Full Text] [Related]
31. Robust cytoplasmic accumulation of phosphorylated TDP-43 in transgenic models of tauopathy.
Clippinger AK; D'Alton S; Lin WL; Gendron TF; Howard J; Borchelt DR; Cannon A; Carlomagno Y; Chakrabarty P; Cook C; Golde TE; Levites Y; Ranum L; Schultheis PJ; Xu G; Petrucelli L; Sahara N; Dickson DW; Giasson B; Lewis J
Acta Neuropathol; 2013 Jul; 126(1):39-50. PubMed ID: 23666556
[TBL] [Abstract][Full Text] [Related]
32. Study of tau pathology in male rTg4510 mice fed with a curcumin derivative Shiga-Y5.
Yanagisawa D; Hamezah HS; Durani LW; Taguchi H; Tooyama I
PLoS One; 2018; 13(12):e0208440. PubMed ID: 30521594
[TBL] [Abstract][Full Text] [Related]
33. The CNS in inbred transgenic models of 4-repeat Tauopathy develops consistent tau seeding capacity yet focal and diverse patterns of protein deposition.
Eskandari-Sedighi G; Daude N; Gapeshina H; Sanders DW; Kamali-Jamil R; Yang J; Shi B; Wille H; Ghetti B; Diamond MI; Janus C; Westaway D
Mol Neurodegener; 2017 Oct; 12(1):72. PubMed ID: 28978354
[TBL] [Abstract][Full Text] [Related]
34. Characteristics of TBS-extractable hyperphosphorylated tau species: aggregation intermediates in rTg4510 mouse brain.
Sahara N; DeTure M; Ren Y; Ebrahim AS; Kang D; Knight J; Volbracht C; Pedersen JT; Dickson DW; Yen SH; Lewis J
J Alzheimers Dis; 2013; 33(1):249-63. PubMed ID: 22941973
[TBL] [Abstract][Full Text] [Related]
35. Analysis of tau post-translational modifications in rTg4510 mice, a model of tau pathology.
Song L; Lu SX; Ouyang X; Melchor J; Lee J; Terracina G; Wang X; Hyde L; Hess JF; Parker EM; Zhang L
Mol Neurodegener; 2015 Mar; 10():14. PubMed ID: 25881209
[TBL] [Abstract][Full Text] [Related]
36. Immunoelectron microscopic and biochemical studies of caspase-cleaved tau in a mouse model of tauopathy.
Lin WL; Dickson DW; Sahara N
J Neuropathol Exp Neurol; 2011 Sep; 70(9):779-87. PubMed ID: 21865886
[TBL] [Abstract][Full Text] [Related]
37. Retarded axonal transport of R406W mutant tau in transgenic mice with a neurodegenerative tauopathy.
Zhang B; Higuchi M; Yoshiyama Y; Ishihara T; Forman MS; Martinez D; Joyce S; Trojanowski JQ; Lee VM
J Neurosci; 2004 May; 24(19):4657-67. PubMed ID: 15140937
[TBL] [Abstract][Full Text] [Related]
38. Neurodegenerative disorder FTDP-17-related tau intron 10 +16C → T mutation increases tau exon 10 splicing and causes tauopathy in transgenic mice.
Umeda T; Yamashita T; Kimura T; Ohnishi K; Takuma H; Ozeki T; Takashima A; Tomiyama T; Mori H
Am J Pathol; 2013 Jul; 183(1):211-25. PubMed ID: 23680655
[TBL] [Abstract][Full Text] [Related]
39. Ultrastructural neuronal pathology in transgenic mice expressing mutant (P301L) human tau.
Lin WL; Lewis J; Yen SH; Hutton M; Dickson DW
J Neurocytol; 2003 Nov; 32(9):1091-105. PubMed ID: 15044841
[TBL] [Abstract][Full Text] [Related]
40. Designing antibodies against LRRK2-targeted tau epitopes.
Hamm M; Ladd TB; Levites Y; Golde TE; Giasson BI; Lewis J
PLoS One; 2018; 13(9):e0204367. PubMed ID: 30261006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
